ENGLEWOOD, Colo., Aug. 13, 2015 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare company focused on developing treatments for urological and related conditions, announced today that its S-1 registration statement relating to the registration of 2,564,872 common shares owned by certain stockholders and issuable to certain warrant holders in Aytu’s predecessor companies was declared effective by the U.S. Securities and Exchange Commission (SEC).
Aytu’s common stock currently trades under the stock symbol “AYTU” on the OTCQB Marketplace. Aytu is not selling any shares of common stock pursuant to this registration statement and will not receive any of the proceeds from a potential sale of shares of common stock by these selling stockholders.
Josh Disbrow, Chief Executive Officer of Aytu BioScience, Inc., stated, “We are pleased to have honored our registration commitment to the shareholders of our predecessor companies, which we believe will add liquidity to our stock as we execute on Aytu’s growth strategy.”
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful.
About Aytu BioScience
Aytu BioScience, Inc. is a specialty healthcare company focused on developing treatments for urological and related conditions. The Company is currently in Phase 3 clinical development for its lead therapeutic candidate Zertane, an orally disintegrating tablet (ODT) formulated specifically for the on-demand treatment of premature ejaculation (PE). The Company’s therapeutic pipeline is supported in part by its first-in-class RedoxSYS® System, which provides the only complete assessment of patients’ redox status and enables identification of a broad variety of disorders where redox is implicated. Clinical studies are underway utilizing the RedoxSYS system in male fertility. The Company also recently acquired and is commercializing its FDA-approved product, ProstaScint® (capromab pendetide), a radio-labeled monoclonal antibody, that targets Prostate Specific Membrane Antigen (PSMA), a protein uniquely expressed by prostate tissue. The Company’s strategy is to develop its core therapeutic and diagnostic assets while building an innovative pipeline of established marketed products and late-stage development assets.
For Investors & Media:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.: jdrumm@tiberend.com; (212) 375-2664
Janine McCargo: jmccargo@tiberend.com; (646) 604-5150
Forward Looking Statement
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our anticipated future clinical and regulatory events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward looking statements are generally written in the future tense and/or are preceded by words such as “may,” “will,” “should,” “forecast,” “could,” “expect,” “suggest,” “believe,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. Such forward-looking statements include, without limitation, statements regarding the potential impact of resale registration of shares on our common stock and the commercialization of our products and product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including without limitation to the risks described in “Risk Factors” in Item 2.01 of our Current Report on Form 8-K filed on April 22, 2015 (filed under our then corporate name of Rosewind Corporation, and in the other reports and documents we file with the Securities and Exchange Commission from time to time. These risks are not exhaustive. Other sections of our Current Report on Form 8-K filed on April 22, 2015, and such other filed reports and documents include additional factors that could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. We assume no obligation to update or supplement forward-looking statements.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aytu-bioscience-announces-effectiveness-of-resale-registration-of-common-shares-for-certain-existing-security-holders-300127930.html
SOURCE Aytu BioScience, Inc.
Help employers find you! Check out all the jobs and post your resume.
